124 related articles for article (PubMed ID: 32071429)
1. The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia.
Godwin CD; Laszlo GS; Wood BL; Correnti CE; Bates OM; Garling EE; Mao ZJ; Beddoe ME; Lunn MC; Humbert O; Kiem HP; Walter RB
Leukemia; 2020 Sep; 34(9):2479-2483. PubMed ID: 32071429
[No Abstract] [Full Text] [Related]
2. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
Laszlo GS; Harrington KH; Gudgeon CJ; Beddoe ME; Fitzgibbon MP; Ries RE; Lamba JK; McIntosh MW; Meshinchi S; Walter RB
Oncotarget; 2016 Jul; 7(28):43281-43294. PubMed ID: 27248327
[TBL] [Abstract][Full Text] [Related]
3. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
[TBL] [Abstract][Full Text] [Related]
4. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.
Arndt C; von Bonin M; Cartellieri M; Feldmann A; Koristka S; Michalk I; Stamova S; Bornhäuser M; Schmitz M; Ehninger G; Bachmann M
Leukemia; 2013 Apr; 27(4):964-7. PubMed ID: 23325142
[No Abstract] [Full Text] [Related]
5. Novel CD33 antibodies unravel localization, biology and therapeutic implications of CD33 isoforms.
Gbadamosi MO; Shastri VM; Hylkema T; Papageorgiou I; Pardo L; Cogle CR; Doty A; Loken MR; Meshinchi S; Lamba JK
Future Oncol; 2021 Jan; 17(3):263-277. PubMed ID: 33356566
[TBL] [Abstract][Full Text] [Related]
6. Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2.
Humbert O; Laszlo GS; Sichel S; Ironside C; Haworth KG; Bates OM; Beddoe ME; Carrillo RR; Kiem HP; Walter RB
Leukemia; 2019 Mar; 33(3):762-808. PubMed ID: 30291334
[No Abstract] [Full Text] [Related]
7. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Krupka C; Kufer P; Kischel R; Zugmaier G; Bögeholz J; Köhnke T; Lichtenegger FS; Schneider S; Metzeler KH; Fiegl M; Spiekermann K; Baeuerle PA; Hiddemann W; Riethmüller G; Subklewe M
Blood; 2014 Jan; 123(3):356-65. PubMed ID: 24300852
[TBL] [Abstract][Full Text] [Related]
8. SRSF1 and PTBP1 Are
van Bergeijk P; Seneviratne U; Aparicio-Prat E; Stanton R; Hasson SA
Mol Cell Biol; 2019 Sep; 39(18):. PubMed ID: 31208978
[TBL] [Abstract][Full Text] [Related]
9. CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry.
Eckel AM; Cherian S; Miller V; Soma L
Cytometry B Clin Cytom; 2020 Mar; 98(2):174-178. PubMed ID: 31622025
[TBL] [Abstract][Full Text] [Related]
10. CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.
Stanchina M; Pastore A; Devlin S; Famulare C; Stein E; Taylor J
J Hematol Oncol; 2019 Aug; 12(1):85. PubMed ID: 31439003
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
[TBL] [Abstract][Full Text] [Related]
12. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive role of CD11b
Hyun SY; Na EJ; Jang JE; Chung H; Kim SJ; Kim JS; Kong JH; Shim KY; Lee JI; Min YH; Cheong JW
Cancer Med; 2020 Oct; 9(19):7007-7017. PubMed ID: 32780544
[TBL] [Abstract][Full Text] [Related]
14. The role of CD33 as therapeutic target in acute myeloid leukemia.
Walter RB
Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
[TBL] [Abstract][Full Text] [Related]
15. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility.
Raj T; Ryan KJ; Replogle JM; Chibnik LB; Rosenkrantz L; Tang A; Rothamel K; Stranger BE; Bennett DA; Evans DA; De Jager PL; Bradshaw EM
Hum Mol Genet; 2014 May; 23(10):2729-36. PubMed ID: 24381305
[TBL] [Abstract][Full Text] [Related]
16. Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia.
Malik M; Chiles J; Xi HS; Medway C; Simpson J; Potluri S; Howard D; Liang Y; Paumi CM; Mukherjee S; Crane P; Younkin S; Fardo DW; Estus S
Hum Mol Genet; 2015 Jun; 24(12):3557-70. PubMed ID: 25762156
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's Disease-Associated Alternative Splicing of
Komuro R; Honda Y; Yanaizu M; Nagahama M; Kino Y
Cells; 2023 Feb; 12(4):. PubMed ID: 36831269
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia fusion genes can be found in CD33-negative cells.
Chen Y; Liu Q; Xing H; Rao Q; Wang M; Mi Y; Wei H; Wang J
Int J Lab Hematol; 2022 Dec; 44(6):1111-1114. PubMed ID: 35915999
[TBL] [Abstract][Full Text] [Related]
19. The Alzheimer's disease-protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool.
Siddiqui SS; Springer SA; Verhagen A; Sundaramurthy V; Alisson-Silva F; Jiang W; Ghosh P; Varki A
J Biol Chem; 2017 Sep; 292(37):15312-15320. PubMed ID: 28747436
[TBL] [Abstract][Full Text] [Related]
20. CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing.
Malik M; Simpson JF; Parikh I; Wilfred BR; Fardo DW; Nelson PT; Estus S
J Neurosci; 2013 Aug; 33(33):13320-5. PubMed ID: 23946390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
